Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024
Reviva Pharmaceuticals (NASDAQ: RVPH) announced it will present positive speech latency data for brilaroxazine in schizophrenia from their Phase 3 RECOVER trial at the CNS Summit 2024. The presentation titled 'Enrichment Based on Speech Latency Enhances Treatment Effects in a Phase III Study of Brilaroxazine' will be delivered as a poster presentation by Dr. Jan Sedway from WCG Clinical on November 12th in Boston, Massachusetts.
Reviva Pharmaceuticals (NASDAQ: RVPH) ha annunciato che presenterà dati positivi sulla latenza del linguaggio per brilaroxazina nella schizofrenia provenienti dal loro studio di Fase 3 RECOVER al CNS Summit 2024. La presentazione intitolata 'L'Arricchimento Basato sulla Latenza del Linguaggio Migliora gli Effetti del Trattamento in uno Studio di Fase III di Brilaroxazina' sarà effettuata come presentazione poster dal Dr. Jan Sedway di WCG Clinical il 12 novembre a Boston, Massachusetts.
Reviva Pharmaceuticals (NASDAQ: RVPH) anunció que presentará datos positivos sobre la latencia del habla para brilaroxazina en la esquizofrenia, provenientes de su prueba de Fase 3 RECOVER en la CNS Summit 2024. La presentación titulada 'El enriquecimiento basado en la latencia del habla mejora los efectos del tratamiento en un estudio de Fase III de brilaroxazina' será realizada como una presentación en cartel por el Dr. Jan Sedway de WCG Clinical el 12 de noviembre en Boston, Massachusetts.
레비바 제약 (NASDAQ: RVPH)는 정신병에서의 브릴라록자진에 대한 긍정적인 언어 지연 데이터를 3상 RECOVER 시험에서 발표할 것이라고 발표했습니다. '언어 지연 기반의 강화가 브릴라록자진의 3상 연구에서 치료 효과를 향상시킨다'라는 제목의 발표는 11월 12일 매사추세츠주 보스턴에서 WCG Clinical의 Dr. Jan Sedway에 의해 포스터 발표로 이루어질 예정입니다.
Reviva Pharmaceuticals (NASDAQ: RVPH) a annoncé qu'elle présentera des données positives sur la latence du discours pour le brilaroxazine dans la schizophrénie, issues de leur essai de phase 3 RECOVER lors du CNS Summit 2024. La présentation intitulée 'L'enrichissement basé sur la latence du discours améliore les effets du traitement dans une étude de phase III de brilaroxazine' sera réalisée sous forme de présentation par affiche par le Dr. Jan Sedway de WCG Clinical le 12 novembre à Boston, Massachusetts.
Reviva Pharmaceuticals (NASDAQ: RVPH) kündigte an, dass sie positive Daten zur Sprachlatenz für Brilaroxazin bei Schizophrenie aus ihrer Phase-3-RECOVER-Studie auf dem CNS Summit 2024 präsentieren werden. Die Präsentation mit dem Titel 'Anreicherung auf Basis der Sprachlatenz verbessert die Behandlungseffekte in einer Phase-III-Studie zu Brilaroxazin' wird am 12. November in Boston, Massachusetts, von Dr. Jan Sedway von WCG Clinical als Posterpräsentation gehalten.
- Positive speech latency data from Phase 3 RECOVER trial to be presented
- Study demonstrates enhanced treatment effects for brilaroxazine in schizophrenia
- None.
CUPERTINO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that positive speech latency data for brilaroxazine in schizophrenia from the Phase 3 RECOVER trial will be presented as a poster presentation at the CNS Summit 2024, taking place November 10-13, in Boston, Massachusetts.
Details for the poster presentation can be found below:
Title: Enrichment Based on Speech Latency Enhances Treatment Effects in a Phase III Study of Brilaroxazine
Poster Board: 10
Date and Time: Tuesday, November 12th from 5:00 - 7:00 PM ET
Presenter: Dr. Jan Sedway, WCG Clinical
Abstracts and additional details can be found at the CNS Summit 2024 website.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
FAQ
What will Reviva Pharmaceuticals (RVPH) present at the CNS Summit 2024?
When and where will RVPH present the Phase 3 RECOVER trial results?
What is the title of RVPH's poster presentation at CNS Summit 2024?
